EMA says conclusion on AstraZeneca vaccine possibly by end of January
The European Medicines Agency (EMA) said on Friday that a decision to authorise the use of the AstraZeneca/Oxford coronavirus vaccine could be made by the end of the month, with the bloc being under pressure to speed out the vaccines rollout.
“Possible conclusion – end of Jan, depending on data and evaluation progress,” the Amsterdam-based agency wrote in a Twitter post.
After having received more data from the company, EMA is expecting Astra Zeneca to submit a conditional marketing application for its #COVID19vaccine next week. Possible conclusion – end of Jan, depending on data and evaluation progress. #EMAPublicMeeting2
— EU Medicines Agency (@EMA_News) January 8, 2021
EMA said it was expecting AstraZeneca to submit a conditional marketing application for the vaccine next week, with its chief, Emer Cooke stressing that the conditional market authorisation “will of course depend on the data we receive and the evaluation progress.”
Should the medicines watchdog recommend the AstraZeneca/Oxford University vaccine, the European Commission will also need to give its nod, through a procedure that is considered a formality.
